ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- A Web-Based Virtual Environment Behavioral Intervention as Cardiovascular Disease and Metabolic Disease Prevention Education in Persons With HIV: Evaluation of the LEARN Randomized Controlled Trial.Journal of medical Internet research · 2026Trial
- Pilot Trial of a Transdiagnostic Cognitive Behavioral Therapy (CBT)-Based Group Intervention to Reduce Psychological Distress, Facilitate Positive Behavior Change, and Mitigate Inflammation in Older People with HIV.AIDS and behavior · 2025Trial
- Perceptions of HIV-Related Comorbidities and Usability of a Virtual Environment for Cardiovascular Disease Prevention Education in Sexual Minority Men With HIV: Formative Phases of a Pilot Randomized Controlled Trial.Journal of medical Internet research · 2024Trial
- Early Warning and Behavioural Intervention on the Cardiovascular Disease Risk in People Living with HIV: A Multicentre Non-Randomized Controlled Trial.Infectious diseases and therapy · 2026Article
- Ending the HIV Epidemic in the United States Among Men Who Have Sex With Men: A Modeling Analysis.Open forum infectious diseases · 2026Article
- Observational
- Sex differences in cardiovascular disease and associated factors in people living with HIV: Evidence from All of Us program.HIV medicine · 2026Article
- Trends and Disparities in Cardiovascular Mortality among HIV-Positive Adults in the United States (2004-2020): A CDC WONDER Database Analysis.Current HIV research · 2026Article
- Comorbidities in pregnant South African women living with HIV and associations with adverse birth outcomes: a prospective cohort study.BMC pregnancy and childbirth · 2025Article
- Disparities in Tobacco Smoking and Risk of Cardiovascular Disease in People With Low Socioeconomic Status or Serious Psychological Distress: A Simulation Analysis.American journal of preventive medicine · 2025Article
- Intervention mapping for systematic development of a community-engaged CVD prevention intervention in ethnic and racial sexual minority men with HIV.Frontiers in public health · 2025Article
- Chronic Illness Perceptions and Cardiovascular Disease Risk Behaviors in Black and Latinx Sexual Minority Men with HIV: A Cross-Sectional Analysis.Nursing reports (Pavia, Italy) · 2024Article
- Human immunodeficiency virus infection is associated with greater risk of pneumonia and readmission after cardiac surgery.JTCVS open · 2024Article
- Disparities in Hypertension Prevalence, Awareness, Treatment, and Control Among Women Living With and Without HIV in the US South.Open forum infectious diseases · 2024Article
- Perspectives of people living with HIV age 50 and over regarding barriers and resources for care.AIDS care · 2023Article
- Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.Circulation · 2023Review
- Vascular dysfunction and body mass index in African adults with HIV.BMC cardiovascular disorders · 2023Article
- Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1.ClinicoEconomics and outcomes research : CEOR · 2023Article
- COVID-19 Outcomes in a US Cohort of Persons Living with HIV (PLWH).Reports (MDPI) · 2022Article
- Cardiovascular disease risk in women living with HIV.Current opinion in HIV and AIDS · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Cardiovascular disease (CVD) is an increasing cause of morbidity among persons living with human immunodeficiency virus (HIV; PLWH). We projected cumulative CVD risk in PLWH in care compared to the US general population and persons HIV-uninfected, but at high risk for HIV. Methods: We used a mathematical model to project cumulative CVD incidence. We simulated a male and female cohort for each of 3 populations: US general population; HIV-uninfected, at high risk for HIV; and PLWH. We incorporated the higher smoking prevalence and increased CVD risk due to smoking into the HIV-infected and HIV-uninfected, at high risk for HIV populations. We incorporated HIV-attributable CVD risk, independent of smoking. Results: For men, life expectancy ranged from 70.2 to 77.5 years and for women from 67.0 to 81.1 years (PLWH, US general population). Without antiretroviral therapy, lifetime CVD risk for HIV-infected males and females was 12.9% and 9.0%. For males, by age 60, cumulative CVD incidence was estimated at 20.5% in PLWH in care, 14.6% in HIV-uninfected high-risk persons, and 12.8% in the US general population. For females, cumulative CVD incidence was projected to be 13.8% in PLWH in care, 9.7% for high-risk HIV-uninfected persons, and 9.4% in the US general population. Lifetime CVD risk was 64.8% for HIV-infected males compared to 54.8% for males in the US general population, but similar among females. Conclusions: CVD risks should be a part of treatment evaluation among PLWH. CVD prevention strategies could offer important health benefits for PLWH and should be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.